Amicus, GSK Extend Their Fabry Disease Collaboration
By Marie Powers
Wednesday, August 8, 2012
Amicus Therapeutics Inc. strengthened ties with partner GlaxoSmithKline plc to develop and commercialize its lead compound, the chaperone migalastat HC1 (Amigal), in Fabry disease.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.